Nuveen Asset Management, LLC Aligos Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $62,667 - $128,949	-60,257 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $49,953 - $292,995	-24,016 Reduced 28.5%	60,257 $172,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $45,357 - $69,893	-3,951 Reduced 4.48%	84,273 $1 Million
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $349,796 - $425,421	24,008 Added 37.39%	88,224 $1.37 Million
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $809,482 - $1.34 Million	39,876 Added 163.83%	64,216 $1.31 Million
Q1 2021 May 17, 2021	BUY	$19.1 - $34.94 $148,789 - $272,182	7,790 Added 47.07%	24,340 $553,000
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $218,460 - $541,847	16,550 New	16,550 $458,000

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.